Alzheimer's drug adoption in US slowed by doctors' skepticism
CHICAGO, Illinois: Nearly nine months into the U.S. launch of Eisai and Biogen's Leqembi, the first drug proven to slow Alzheimer's progression, it faces an unexpected barrier to widespread use: skepticism among some doctors regarding the treatment's efficacy.
While Alzheimer's experts foresaw challenges due to Leqembi's requirements-such as additional diagnostic tests, twice-monthly infusions, and regular brain